The role of angiotensin II receptor antagonists in hypertension management: Focus on candesartan cilexetil

G. Mancia, G. Grassi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for the management of hypertension during the past 30 years. The aim of this article is to review the recommendations of the most recent of these - the 1999 WHO-ISH guidelines - as well as previous similar documents, including the earlier 1993 WHO-ISH guidelines and the US Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure, and to outline the supportive evidence that has contributed to their formulation. Moreover, the 1999 guidelines have added a new class of antihypertensive drugs, the angiotensin II receptor antagonists, to the armamentarium of therapeutic agents recommended for the early treatment of hypertension. Particular attention will be paid in this paper to the role of these agents in hypertension, focusing on candesartan ciletexil as a representative of its class.

Original languageEnglish
JournalJournal of Human Hypertension
Volume14
Issue numberSUPPL. 2
Publication statusPublished - 2000

Fingerprint

Angiotensin Receptor Antagonists
Hypertension
Guidelines
Therapeutics
Antihypertensive Agents
Patient Care
candesartan cilexetil
Health
Population

Keywords

  • Angiotensin II receptor antagonist
  • Candesartan cilexetil
  • Hypertension
  • WHO-ISH guidelines

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The role of angiotensin II receptor antagonists in hypertension management : Focus on candesartan cilexetil. / Mancia, G.; Grassi, G.

In: Journal of Human Hypertension, Vol. 14, No. SUPPL. 2, 2000.

Research output: Contribution to journalArticle

@article{cff6115837ec45ac9943a07171c590b9,
title = "The role of angiotensin II receptor antagonists in hypertension management: Focus on candesartan cilexetil",
abstract = "The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for the management of hypertension during the past 30 years. The aim of this article is to review the recommendations of the most recent of these - the 1999 WHO-ISH guidelines - as well as previous similar documents, including the earlier 1993 WHO-ISH guidelines and the US Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure, and to outline the supportive evidence that has contributed to their formulation. Moreover, the 1999 guidelines have added a new class of antihypertensive drugs, the angiotensin II receptor antagonists, to the armamentarium of therapeutic agents recommended for the early treatment of hypertension. Particular attention will be paid in this paper to the role of these agents in hypertension, focusing on candesartan ciletexil as a representative of its class.",
keywords = "Angiotensin II receptor antagonist, Candesartan cilexetil, Hypertension, WHO-ISH guidelines",
author = "G. Mancia and G. Grassi",
year = "2000",
language = "English",
volume = "14",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "SUPPL. 2",

}

TY - JOUR

T1 - The role of angiotensin II receptor antagonists in hypertension management

T2 - Focus on candesartan cilexetil

AU - Mancia, G.

AU - Grassi, G.

PY - 2000

Y1 - 2000

N2 - The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for the management of hypertension during the past 30 years. The aim of this article is to review the recommendations of the most recent of these - the 1999 WHO-ISH guidelines - as well as previous similar documents, including the earlier 1993 WHO-ISH guidelines and the US Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure, and to outline the supportive evidence that has contributed to their formulation. Moreover, the 1999 guidelines have added a new class of antihypertensive drugs, the angiotensin II receptor antagonists, to the armamentarium of therapeutic agents recommended for the early treatment of hypertension. Particular attention will be paid in this paper to the role of these agents in hypertension, focusing on candesartan ciletexil as a representative of its class.

AB - The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for the management of hypertension during the past 30 years. The aim of this article is to review the recommendations of the most recent of these - the 1999 WHO-ISH guidelines - as well as previous similar documents, including the earlier 1993 WHO-ISH guidelines and the US Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure, and to outline the supportive evidence that has contributed to their formulation. Moreover, the 1999 guidelines have added a new class of antihypertensive drugs, the angiotensin II receptor antagonists, to the armamentarium of therapeutic agents recommended for the early treatment of hypertension. Particular attention will be paid in this paper to the role of these agents in hypertension, focusing on candesartan ciletexil as a representative of its class.

KW - Angiotensin II receptor antagonist

KW - Candesartan cilexetil

KW - Hypertension

KW - WHO-ISH guidelines

UR - http://www.scopus.com/inward/record.url?scp=0033765643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033765643&partnerID=8YFLogxK

M3 - Article

C2 - 11086630

AN - SCOPUS:0033765643

VL - 14

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - SUPPL. 2

ER -